Putnam Associates’ Dr. Warren Whyte’s Research Published »
Putnam Associates’ Life Sciences Consultant Dr. Warren A. Whyte was the lead author of a paper published in the April issue of Cell...
Read More
Putnam Perspective: Orphan Drugs »
Putnam Associates reports on how orphan diseases represent areas of significant unmet need. There are approximately 7,000 recognized orphan diseases yet only about 200 approved products...
Read More
Boston’s Third Rock Ventures Closes $516 Fund, Boston Globe 3/16/13 »
Third Rock Ventures, a Boston venture capital firm, has closed a new $516 million fund and plans to begin investing in innovative life-sciences start-ups in...
Read More
Case Studies
Product Launch Strategy »
Situation
A pharmaceutical company anticipated market approval for a drug that served patients in a highly competitive category of infectious disease. The...
Read More
